The Lancet Oncology Q1 Unclaimed

Lancet Publishing Group United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

The Lancet Oncology is a journal indexed in SJR in Oncology with an H index of 305. Journal with a Single blind Peer Review review system, and It has a price of 2395 €. The scope of the journal is focused on Oncology, Cancer, . It has an SJR impact factor of 15,65 and it has a best quartile of Q1. It is published in English.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

WOS Scopus
Categories: Oncology (Q1)
Price

2395 €

Gold OA

-

Green OA

0 €

Non OA

Metrics

The Lancet Oncology

15,65

SJR Impact factor

305

H Index

618

Total Docs (Last Year)

1958

Total Docs (3 years)

8994

Total Refs

18292

Total Cites (3 years)

540

Citable Docs (3 years)

31

Cites/Doc (2 years)

14,55

Ref/Doc


Best articles

A new approach to managing prostate cancer is essential

View more

A paperchase

View more

Adjuvant interferon alfa treatment for patients with malignant melanoma stimulates transporter proteins associated with antigen processing and proteasome activator 28

View more

Alan Coates -CEO of the Australian Cancer Society

View more

Allan van Oosterom, President of the EORTC

View more

Alternative cancer cures

View more

Alternative medicine and cancer patients in less developed countries

View more

Amgen's point of view on epoetins

View more

An extra defence against skin cancer?

View more

Association of the British Pharmaceutical Industry says...

View more

Australia approves thalidomide

View more

Australian cancer survival figures greatly improved

View more
SHOW MORE ARTICLES

Australian scientists design novel antiangiogenic weapon

View more

Breast cancer in women after treatment for Hodgkin's disease

View more

Breast reconstruction cannot exorcise phantom pain

View more

Bring back the acetyls - a novel anticancer movement

View more

Canadian researchers uncover vital new clues in cancer

View more

Cancer and ethnic minorities

View more

Cancer Institute at Chennai: a model for resource-poor countries

View more

Cancer sites for children are few and far between

View more

CCI-779: a new targeted anticancer agent

View more

Chemoprevention: eat ginger, rub on pomegranate

View more

Chemotherapy and anaesthetic drugs: too little is known

View more

Chlorophyllin reduces risk of aflatoxin-induced liver cancer

View more

Comments

No comments ... Be the first to comment!